Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

Scientists have discovered a previously unknown type of immune cell that develops in people who successfully fight off cancer. Unlike other killer T cells, these home in on multiple cancer ...

The body’s defense system against infection also fights tumors, generating tumor resident stem-like T cells and killer T cells that express inhibitory receptors such as PD-1. When PD-1 binds to PD-L1 ...

Old cells need to be cleared by the immune system. If they aren't, inflammation follows. Now, researchers have leveraged CAR-T technology to help with this task.

Research using high resolution, three dimensional imaging reveals new insights on how killer T cells swiftly kill target after target.

Exhausted killer T cells expressed more ADRB1 receptors than their functional counterparts, allowing the T cells to "listen" to the noradrenaline released by the nerves.

Natural killer T cells possess innate-like properties that make them uniquely equipped to fight solid tumors. Specifically, they express a T cell receptor that recognizes glycolipid antigens ...

Gene variants associated with leukemia can produce 'rogue' immune cells that drive autoimmune diseases, according to a new study from the Garvan Institute of Medical Research.

Cancer immunotherapy strategy equips T cells with molecular GPS that lets them home in on brain tumors and sites of neuroinflammation.

The rising cancer treatment and technology known as CAR-T uses a patient’s own blood cells to cure their malignancies.

Natural killer T cells possess innate-like properties that make them uniquely equipped to fight solid tumors. Specifically, they express a T cell receptor that recognizes glycolipid antigens ...